Real-world check on CMV drugs in transplant patients
NCT ID NCT04690933
First seen Jan 05, 2026 · Last updated May 23, 2026 · Updated 21 times
Summary
This study followed 400 stem cell transplant recipients to see how well anti-CMV medications work in everyday hospital care. Researchers tracked infections, drug resistance, and side effects. The goal was to improve treatment guidelines for these high-risk patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC STEM CELL TRANSPLANTATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
APHP
Paris, France
-
CHU
Amiens, France
-
CHU
Angers, France
-
CHU
Besançon, France
-
CHU
Bordeaux, France
-
CHU
Caen, France
-
CHU
Clermont-Ferrand, France
-
CHU
Grenoble, France
-
CHU
Montpellier, France
-
CHU
Nancy, France
-
CHU
Poitiers, France
-
CHU
Rouen, France
-
CHU
Saint-Etienne, France
-
CHU
Strasbourg, France
-
CHU de LIMOGES
Limoges, Limoges, 87045, France
-
HCL
Lyon, France
Conditions
Explore the condition pages connected to this study.